ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1136

Challenges in Diagnosing VEXAS Syndrome: Delayed Diagnosis, Misdiagnosis, and Associations with Specific Gene Mutations

Paula García Escudero1, Marta López i Gómez2, Marta López Maraver3, PALOMA VELA4, María Rodríguez Laguna5, carolina Merino6, Ana Victoria Orenes Vera7, Clara García Belando8, Diego Dios Santos9, Jose Alberto Miranda Filloy10, Francisco Javier Toyos Sáenz de Miera11, Alicia Garcia Dorta12, Ignacio Vázquez13, José Ángel Hernández Beriain14, MARIA ELVIRA DIEZ ALVAREZ15, Marta Ibáñez Martínez16, Beatriz Frade Sosa17, Judit Font Urgelles18, Meritxell Salles Lizarzaburu19, Elena Riera Alonso20, Ernesto Trallero Araguás21, Berta Magallanes López22, Joaquín Belzunegui Otano23, Carlos de Miguel Sánchez24, Zuriñe Ortiz de Zárate Caballero25 and Jaime Calvo Alén26, 1Hospital Universitario Araba, Bilbao, Spain, 2Hospital Universitario de Araba, Pamplona, Spain, 3Hospital Universitario de Araba, Vitoria, Spain, 4Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, 5H. Clínico San Carlos, Madrid, Spain, 6Rheumatology Department Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, 7H. Arnau de Vilanova, Valencia, Spain, 8Hospital Los Arcos del Mar Menor, Murcia, Spain, 9Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 10C. H. U. Lucus Augusti, Lugo, Spain, 11Hospital Virgen Macarena, Sevilla, Spain, 12Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 13H. U. Dr. Peset, Valencia, Spain, 14Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, 15Rheumatology, Hospital Universitario de León, León, Spain, 16C. A. U. de Salamanca, Salamanca, Spain, 17Hospital Clínic de Barcelona, Barcelona, Spain, 18Hospital Universitario Germans Trías i Pujol, Barcelona, Spain, 19C. H. de Manresa - Fundació Althaia, Barcelona, Spain, 20Hospital Universitario Mútua Terrassa, Barcelona, Spain, 21Department of Rheumatology, Hospital Universitario Vall d'Hebron, Barcelona, Spain, 22Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 23Hospital Universitario Donosti, Donosti, Spain, 24Hospital Universitario de Araba, Hematology, VItoria, Spain, 25Hospital Universitario de Araba, Internal Medicine, Vitoria, Spain, 26Hospital Universitario Araba, Vitoria, Spain

Meeting: ACR Convergence 2023

Keywords: Autoinflammatory diseases, classification criteria, genetics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The newly described VEXAS syndrome is a very heterogenous disease with rheumatologic and hematologic manifestations, caused by somatic mutations affecting UBA1 gene, that still requires a precise definition. This report aims to address diagnostic challenges such as delays in diagnosis, misdiagnosis, and the clinical associations observed between specific genetic mutations and VEXAS patients (VP).

Methods: A comprehensive survey covering the whole country, which included 126 Spanish hospitals with rheumatologic units, was performed to identify all the VP observed in those units. VP were defined as compatible clinical picture plus characteristic BMB and/or confirmed genetic UBA1 gene mutations. Demographic and clinical data, along with the timing of initial symptoms, initial and final diagnoses, and specific gene mutations identified in each case, were gathered from medical records. Descriptive analyses were conducted employing standard tests.

Results: Twenty-eight VP were identified. Mean age at onset of symptoms was 65.46 (±SD 9.44/range 40-78) years of age, while mean age at final diagnostic was 70.96 (±SD 8.92/range 46-83) years of age.Median diagnostic delay was 65.34 (±SD 41.73) months and median time from first symptom appearance to Rheumatology referral was 26.29 (±SD 41.73) months. Diagnoses prior to VEXAS syndrome are summarised in Table 1. Twenty-six (92.85%) patients underwent bone marrow biopsy; presence of at least 1 cytoplasmic vacuole was described in 23 cases. Genetic tests were performed in 23 (82.14%) patients. Within our cohort, among the three primary causative variants, 10 patients exhibited an M41L mutation, 8 patients had an M41T mutation, and 3 patients presented an M41V mutation. One patient presented a novel variation affecting c.209T >A, causing a leucine to histidine change, this alteration has not been previously described in other studies to our knowledge at the time of this publication. Finally, data regarding specific mutation was missed in a case. The mutation causing a change to leucine was associated with a phenotype more limited to the skin and joints, with absence of other manifestations as chondritis, hearing loss, or pulmonary involvement. In contrast, the threonine mutation was associated with a broader repertoire of clinical manifestations. Most of these associations were numerical rather than statistically significant (with the exceptions of negative association between hearing loss and leucine mutation and the positive one of chondritis with threonine) due to sample size limitations (Table 2). Finally, out of the 3 (10.71%) patients who died, 2 had leucine and 1 threonine mutations.

Conclusion: The VEXAS syndrome presents a significant delay in its detection as it is quite common its misdiagnosis for other multisystemic entities. Leucine mutation seems to be more associated with cutaneous and articular involvement, whereas the threonine mutation is more associated with chondritis and a more multi-organ clinical picture. These associations need further clarification through larger cohorts, which should also investigate the role of the novel mutation (c.209T >A: p.L70H) identified in this particular cohort.

Supporting image 1

Table 1. Most frequent diagnostics prior to VEXAS.

Supporting image 2

Table 2. Clinical associations according to mutation type.


Disclosures: P. García Escudero: None; M. López i Gómez: None; M. López Maraver: None; P. VELA: AbbVie/Abbott, 5, AstraZeneca, 5, Eli Lilly, 5, 6, GlaxoSmithKlein(GSK), 6, Novartis, 5, Pfizer, 5; M. Rodríguez Laguna: None; c. Merino: None; A. Orenes Vera: None; C. García Belando: None; D. Dios Santos: None; J. Miranda Filloy: None; F. Toyos Sáenz de Miera: None; A. Garcia Dorta: None; I. Vázquez: None; J. Hernández Beriain: None; M. DIEZ ALVAREZ: None; M. Ibáñez Martínez: None; B. Frade Sosa: None; J. Font Urgelles: None; M. Salles Lizarzaburu: None; E. Riera Alonso: None; E. Trallero Araguás: None; B. Magallanes López: None; J. Belzunegui Otano: None; C. de Miguel Sánchez: None; Z. Ortiz de Zárate Caballero: None; J. Calvo Alén: None.

To cite this abstract in AMA style:

García Escudero P, López i Gómez M, López Maraver M, VELA P, Rodríguez Laguna M, Merino c, Orenes Vera A, García Belando C, Dios Santos D, Miranda Filloy J, Toyos Sáenz de Miera F, Garcia Dorta A, Vázquez I, Hernández Beriain J, DIEZ ALVAREZ M, Ibáñez Martínez M, Frade Sosa B, Font Urgelles J, Salles Lizarzaburu M, Riera Alonso E, Trallero Araguás E, Magallanes López B, Belzunegui Otano J, de Miguel Sánchez C, Ortiz de Zárate Caballero Z, Calvo Alén J. Challenges in Diagnosing VEXAS Syndrome: Delayed Diagnosis, Misdiagnosis, and Associations with Specific Gene Mutations [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/challenges-in-diagnosing-vexas-syndrome-delayed-diagnosis-misdiagnosis-and-associations-with-specific-gene-mutations/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/challenges-in-diagnosing-vexas-syndrome-delayed-diagnosis-misdiagnosis-and-associations-with-specific-gene-mutations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology